The iShares U.S. Healthcare ETF (IHE) delivered higher returns than the Health Care Select Sector SPDR (XLV) over the past 12 months [1].
This performance gap highlights the trade-off between aggressive growth in pharmaceutical sectors and the stability of broader healthcare indices. Investors must now weigh immediate historical gains against long-term management costs.
Analysis of the two funds shows that IHE focuses more heavily on the pharmaceutical industry [1], [2]. This concentration allowed the fund to outperform XLV during the most recent annual cycle [1], [2]. However, this higher return comes with a different cost structure than its competitor.
XLV provides a broader focus across the healthcare sector [1], [2]. While its recent returns lagged behind those of IHE, the fund maintains a significantly lower expense ratio [1], [2]. This makes it a more cost-efficient option for investors seeking wide exposure to healthcare without the higher fees associated with more concentrated funds.
Both ETFs are listed in the U.S. and serve as primary vehicles for sector-specific investment [1], [2]. The choice between the two depends on whether a trader prioritizes the pharmaceutical-heavy returns of IHE or the lower-cost, diversified approach of XLV [1], [2].
Market analysts said that the divergence in performance reflects the volatility of pharma stocks compared to the wider healthcare market — a trend that can shift rapidly based on regulatory changes or new drug approvals [1], [2].
“IHE delivered higher returns than the Health Care Select Sector SPDR (XLV) over the past 12 months”
The performance difference between IHE and XLV illustrates a classic investment tension between sector concentration and diversification. IHE's pharmaceutical tilt provided a short-term edge, but XLV's lower expense ratio offers a structural advantage for long-term holders. This suggests that while pharma-heavy funds can capture rapid growth, broader ETFs may provide more sustainable cost-adjusted returns over time.
